Cargando…

Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas

BACKGROUND: The majority of genetic biomarkers for human cancers are defined by statistical screening of high-throughput genomics data. While a large number of genetic biomarkers have been proposed for diagnostic and prognostic applications, only a small number have been applied in the clinic. Simil...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Lars Rønn, Campos, Benito, Winther, Ole, Sgroi, Dennis C, Karger, Barry L, Brusic, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290786/
https://www.ncbi.nlm.nih.gov/pubmed/25521819
http://dx.doi.org/10.1186/1755-8794-7-S3-S2
_version_ 1782352302892384256
author Olsen, Lars Rønn
Campos, Benito
Winther, Ole
Sgroi, Dennis C
Karger, Barry L
Brusic, Vladimir
author_facet Olsen, Lars Rønn
Campos, Benito
Winther, Ole
Sgroi, Dennis C
Karger, Barry L
Brusic, Vladimir
author_sort Olsen, Lars Rønn
collection PubMed
description BACKGROUND: The majority of genetic biomarkers for human cancers are defined by statistical screening of high-throughput genomics data. While a large number of genetic biomarkers have been proposed for diagnostic and prognostic applications, only a small number have been applied in the clinic. Similarly, the use of proteomics methods for the discovery of cancer biomarkers is increasing. The emerging field of proteogenomics seeks to enrich the value of genomics and proteomics approaches by studying the intersection of genomics and proteomics data. This task is challenging due to the complex nature of transcriptional and translation regulatory mechanisms and the disparities between genomic and proteomic data from the same samples. In this study, we have examined tumor antigens as potential biomarkers for breast cancer using genomics and proteomics data from previously reported laser capture microdissected ER+ tumor samples. RESULTS: We applied proteogenomic analyses to study the genetic aberrations of 32 tumor antigens determined in the proteomic data. We found that tumor antigens that are aberrantly expressed at the genetic level and expressed at the protein level, are likely involved in perturbing pathways directly linked to the hallmarks of cancer. The results found by proteogenomic analysis of the 32 tumor antigens studied here, capture largely the same pathway irregularities as those elucidated from large-scale screening of genomics analyses, where several thousands of genes are often found to be perturbed. CONCLUSION: Tumor antigens are a group of proteins recognized by the cells of the immune system. Specifically, they are recognized in tumor cells where they are present in larger than usual amounts, or are physiochemically altered to a degree at which they no longer resemble native human proteins. This proteogenomic analysis of 32 tumor antigens suggests that tumor antigens have the potential to be highly specific biomarkers for different cancers.
format Online
Article
Text
id pubmed-4290786
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42907862015-01-15 Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas Olsen, Lars Rønn Campos, Benito Winther, Ole Sgroi, Dennis C Karger, Barry L Brusic, Vladimir BMC Med Genomics Research BACKGROUND: The majority of genetic biomarkers for human cancers are defined by statistical screening of high-throughput genomics data. While a large number of genetic biomarkers have been proposed for diagnostic and prognostic applications, only a small number have been applied in the clinic. Similarly, the use of proteomics methods for the discovery of cancer biomarkers is increasing. The emerging field of proteogenomics seeks to enrich the value of genomics and proteomics approaches by studying the intersection of genomics and proteomics data. This task is challenging due to the complex nature of transcriptional and translation regulatory mechanisms and the disparities between genomic and proteomic data from the same samples. In this study, we have examined tumor antigens as potential biomarkers for breast cancer using genomics and proteomics data from previously reported laser capture microdissected ER+ tumor samples. RESULTS: We applied proteogenomic analyses to study the genetic aberrations of 32 tumor antigens determined in the proteomic data. We found that tumor antigens that are aberrantly expressed at the genetic level and expressed at the protein level, are likely involved in perturbing pathways directly linked to the hallmarks of cancer. The results found by proteogenomic analysis of the 32 tumor antigens studied here, capture largely the same pathway irregularities as those elucidated from large-scale screening of genomics analyses, where several thousands of genes are often found to be perturbed. CONCLUSION: Tumor antigens are a group of proteins recognized by the cells of the immune system. Specifically, they are recognized in tumor cells where they are present in larger than usual amounts, or are physiochemically altered to a degree at which they no longer resemble native human proteins. This proteogenomic analysis of 32 tumor antigens suggests that tumor antigens have the potential to be highly specific biomarkers for different cancers. BioMed Central 2014-12-08 /pmc/articles/PMC4290786/ /pubmed/25521819 http://dx.doi.org/10.1186/1755-8794-7-S3-S2 Text en Copyright © 2014 Olsen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Olsen, Lars Rønn
Campos, Benito
Winther, Ole
Sgroi, Dennis C
Karger, Barry L
Brusic, Vladimir
Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
title Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
title_full Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
title_fullStr Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
title_full_unstemmed Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
title_short Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
title_sort tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290786/
https://www.ncbi.nlm.nih.gov/pubmed/25521819
http://dx.doi.org/10.1186/1755-8794-7-S3-S2
work_keys_str_mv AT olsenlarsrønn tumorantigensasproteogenomicbiomarkersininvasiveductalcarcinomas
AT camposbenito tumorantigensasproteogenomicbiomarkersininvasiveductalcarcinomas
AT wintherole tumorantigensasproteogenomicbiomarkersininvasiveductalcarcinomas
AT sgroidennisc tumorantigensasproteogenomicbiomarkersininvasiveductalcarcinomas
AT kargerbarryl tumorantigensasproteogenomicbiomarkersininvasiveductalcarcinomas
AT brusicvladimir tumorantigensasproteogenomicbiomarkersininvasiveductalcarcinomas